|
Gene: PHB |
Gene summary for PHB |
Gene summary. |
Gene information | Species | Human | Gene symbol | PHB | Gene ID | 5245 |
Gene name | prohibitin | |
Gene Alias | HEL-215 | |
Cytomap | 17q21.33 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A8K401 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5245 | PHB | AEH-subject1 | Human | Endometrium | AEH | 3.58e-06 | -2.62e-01 | -0.3059 |
5245 | PHB | AEH-subject2 | Human | Endometrium | AEH | 1.17e-09 | -3.31e-01 | -0.2525 |
5245 | PHB | AEH-subject3 | Human | Endometrium | AEH | 3.07e-03 | -1.41e-01 | -0.2576 |
5245 | PHB | AEH-subject4 | Human | Endometrium | AEH | 5.01e-06 | -3.02e-01 | -0.2657 |
5245 | PHB | AEH-subject5 | Human | Endometrium | AEH | 4.44e-05 | -2.44e-01 | -0.2953 |
5245 | PHB | EEC-subject1 | Human | Endometrium | EEC | 3.25e-15 | -3.62e-01 | -0.2682 |
5245 | PHB | EEC-subject2 | Human | Endometrium | EEC | 5.27e-07 | -3.06e-01 | -0.2607 |
5245 | PHB | EEC-subject3 | Human | Endometrium | EEC | 1.32e-43 | -4.10e-01 | -0.2525 |
5245 | PHB | EEC-subject4 | Human | Endometrium | EEC | 3.05e-02 | -1.64e-02 | -0.2571 |
5245 | PHB | EEC-subject5 | Human | Endometrium | EEC | 2.14e-03 | -1.68e-01 | -0.249 |
5245 | PHB | GSM5276934 | Human | Endometrium | EEC | 3.54e-06 | -2.81e-01 | -0.0913 |
5245 | PHB | GSM5276937 | Human | Endometrium | EEC | 2.24e-04 | -2.59e-01 | -0.0897 |
5245 | PHB | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.52e-25 | -2.58e-01 | -0.1869 |
5245 | PHB | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.79e-27 | -1.94e-01 | -0.1875 |
5245 | PHB | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.18e-27 | -1.42e-01 | -0.1883 |
5245 | PHB | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.02e-27 | -2.11e-01 | -0.1934 |
5245 | PHB | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 3.71e-44 | -1.24e-01 | -0.1917 |
5245 | PHB | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.06e-36 | -1.44e-01 | -0.1916 |
5245 | PHB | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 3.76e-03 | -2.20e-02 | -0.1269 |
5245 | PHB | LZE2D | Human | Esophagus | HGIN | 1.73e-02 | 1.75e-01 | 0.0642 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007170911 | Liver | HCC | membrane assembly | 34/7958 | 50/18723 | 2.38e-04 | 1.79e-03 | 34 |
GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
GO:00075962 | Liver | HCC | blood coagulation | 118/7958 | 217/18723 | 2.63e-04 | 1.94e-03 | 118 |
GO:007145311 | Liver | HCC | cellular response to oxygen levels | 98/7958 | 177/18723 | 3.63e-04 | 2.52e-03 | 98 |
GO:190307812 | Liver | HCC | positive regulation of protein localization to plasma membrane | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
GO:003629411 | Liver | HCC | cellular response to decreased oxygen levels | 90/7958 | 161/18723 | 4.03e-04 | 2.72e-03 | 90 |
GO:00718975 | Liver | HCC | DNA biosynthetic process | 99/7958 | 180/18723 | 4.66e-04 | 3.08e-03 | 99 |
GO:00075992 | Liver | HCC | hemostasis | 119/7958 | 222/18723 | 5.25e-04 | 3.41e-03 | 119 |
GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
GO:00447881 | Liver | HCC | modulation by host of viral process | 22/7958 | 30/18723 | 6.14e-04 | 3.82e-03 | 22 |
GO:0098732 | Liver | HCC | macromolecule deacylation | 67/7958 | 116/18723 | 6.46e-04 | 3.99e-03 | 67 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00900683 | Liver | HCC | positive regulation of cell cycle process | 125/7958 | 236/18723 | 7.21e-04 | 4.40e-03 | 125 |
GO:19026007 | Liver | HCC | proton transmembrane transport | 87/7958 | 157/18723 | 7.27e-04 | 4.42e-03 | 87 |
GO:007145611 | Liver | HCC | cellular response to hypoxia | 84/7958 | 151/18723 | 7.57e-04 | 4.56e-03 | 84 |
GO:003052021 | Liver | HCC | intracellular estrogen receptor signaling pathway | 35/7958 | 54/18723 | 7.73e-04 | 4.65e-03 | 35 |
GO:00434097 | Liver | HCC | negative regulation of MAPK cascade | 98/7958 | 180/18723 | 7.88e-04 | 4.74e-03 | 98 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:00508172 | Liver | HCC | coagulation | 118/7958 | 222/18723 | 8.41e-04 | 5.03e-03 | 118 |
GO:004593111 | Liver | HCC | positive regulation of mitotic cell cycle | 69/7958 | 121/18723 | 8.79e-04 | 5.20e-03 | 69 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
EFNB2 | EPHB1 | EFNB2_EPHB1 | EPHB | Breast | DCIS |
EFNB1 | EPHB1 | EFNB1_EPHB1 | EPHB | Breast | Healthy |
EFNB2 | EPHB1 | EFNB2_EPHB1 | EPHB | Breast | Healthy |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | Cervix | CC |
EFNB1 | EPHB2 | EFNB1_EPHB2 | EPHB | Cervix | CC |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | Cervix | CC |
EFNB1 | EPHB2 | EFNB1_EPHB2 | EPHB | CRC | AD |
EFNB1 | EPHB4 | EFNB1_EPHB4 | EPHB | CRC | AD |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | CRC | AD |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | AD |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | ADJ |
EFNB1 | EPHB2 | EFNB1_EPHB2 | EPHB | CRC | ADJ |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | CRC | ADJ |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | CRC |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | CRC | CRC |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | FAP |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | CRC | FAP |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | Healthy |
EFNB2 | EPHB2 | EFNB2_EPHB2 | EPHB | CRC | Healthy |
EFNA5 | EPHB2 | EFNA5_EPHB2 | EPHA | CRC | MSI-H |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHB | SNV | Missense_Mutation | novel | c.590G>C | p.Arg197Thr | p.R197T | P35232 | protein_coding | deleterious(0.02) | possibly_damaging(0.848) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
PHB | insertion | Nonsense_Mutation | novel | c.69_70insTATTCAAAAAGAGCTTCCCAGCCCACTTCCTAGTTGGATGTGC | p.Asn24TyrfsTer11 | p.N24Yfs*11 | P35232 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
PHB | insertion | Nonsense_Mutation | novel | c.249_250insTTCTCATAGACAGGGAAATAAGCTCAGGTTGGCTAAGGCTTAGAGAG | p.Asp84PhefsTer3 | p.D84Ffs*3 | P35232 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
PHB | SNV | Missense_Mutation | c.349N>T | p.Arg117Cys | p.R117C | P35232 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PHB | SNV | Missense_Mutation | c.466G>A | p.Glu156Lys | p.E156K | P35232 | protein_coding | tolerated(0.36) | benign(0.314) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
PHB | SNV | Missense_Mutation | c.347N>C | p.Glu116Ala | p.E116A | P35232 | protein_coding | deleterious(0.01) | probably_damaging(0.933) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PHB | SNV | Missense_Mutation | c.349C>T | p.Arg117Cys | p.R117C | P35232 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PHB | SNV | Missense_Mutation | rs377541756 | c.626N>T | p.Ala209Val | p.A209V | P35232 | protein_coding | deleterious(0.04) | benign(0.327) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | novel | c.175C>T | p.Pro59Ser | p.P59S | P35232 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PHB | SNV | Missense_Mutation | rs759272172 | c.397N>T | p.Arg133Cys | p.R133C | P35232 | protein_coding | tolerated(0.06) | benign(0.021) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |